Loading page
Loading page
Loading substance route
Effects vary widely by individual, dose, and context.
The physical effects of pyrazolam can be broken down into several components which progressively intensify proportional to dosage.
The general head space of pyrazolam is described by many as one of mild sedation and proportionlly intense anxiety suppression. It contains a large number of typical depressant cognitive effects.
These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
There is considerable risk of physical harm when taking these combinations, they should be avoided where possible.
These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
Pyrazolam is described as extremely psychologically addictive, with compulsive redosing commonly reported as a cognitive effect. However, its comparatively limited sedative and euphoric effects relative to other benzodiazepines may somewhat reduce recreational appeal and abuse potential.
Physical dependence develops with regular use. Withdrawal following a few weeks or longer of steady dosing can be potentially life-threatening, with symptoms including hypertension and seizures; abrupt discontinuation after extended use may result in death. Gradual tapering over weeks is strongly recommended.
Pyrazolam likely has a low toxicity relative to dose when used alone. Fatal overdose may occur when combined with other depressants such as opioids, alcohol, barbiturates, or other GABAergic substances. Benzodiazepine overdose is a medical emergency that can lead to coma, permanent brain injury, or death.
While benzodiazepines have anticonvulsant properties during use, abrupt discontinuation after regular use can cause potentially fatal seizures. Paradoxical seizure reactions during use are rare in the general population, with an incidence rate below 1%, occurring more frequently in epileptics and high-dosage regimes.
Pyrazolam was originally developed during the 1970s by a research team led by Leo Sternbach at Hoffman-La Roche, the pharmaceutical company responsible for discovering many clinically significant benzodiazepines. Despite its initial synthesis during this prolific period of benzodiazepine research,…
Controlled under the Controlled Drugs and Substances Act as part of the blanket scheduling of all benzodiazepines. Possession, trafficking, and production without authorization carry criminal penalties.
Listed as a Schedule III controlled substance since 2017. Production, distribution, and possession are regulated under federal drug control legislation.
Specifically named as a controlled substance under Verzeichnis E (Schedule E) of Swiss narcotics legislation. Unauthorized possession and distribution are prohibited.
Controlled as a Class C substance under the Misuse of Drugs Act 1971 since May 31, 2017. Prior to this, a Temporary Class Drug Order (TCDO) issued in December 2016 had already prohibited personal possession, not just import and supply. It is illegal to possess, produce, or supply.
Controlled under the Neue-psychoaktive-Stoffe-Gesetz (New Psychoactive Substances Act) since July 18, 2019. Production, import with intent to market, administration to others, and trading are punishable offenses. Possession is technically illegal but not subject to criminal penalty.
Classified as a controlled narcotic substance under Swedish drug legislation. Possession, sale, and distribution are prohibited.
Classified as an illegal drug under Turkish drug control laws. Possession, production, supply, and importation are all criminal offenses.
13 sources cited
